Bioject Medical Technologies Inc. Release: Biojector®2000 Data Presented in Vical Incorporated's Pandemic Influenza DNA Vaccine Human Trial

PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free injection therapy systems, today announced that the Biojector® 2000 (B2000) was used in Vical Inc.’s (Vical) first Phase 1 human trial of H5N1 pandemic influenza DNA vaccines formulated with Vical’s Vaxfectin® adjuvant. Data were presented today by Vical at the IBC Life Sciences Next Generation Vaccines conference held in Maryland.